Synakis Corp.

Toronto, CA · 2 known investors

Synakis develops biomaterial-based treatments for ocular diseases using a proprietary hydrogel technology for vitreous replacement and therapeutic delivery. The company targets patients with retinal detachment, glaucoma, and retinal degenerative diseases.